Antimicrobial

Recce Pharmaceuticals Receives $2 Million Grant from U.S. Department of Defense for RECCE® 327 Gel

Funding to accelerate development of RECCE® 327 Gel (R327G) for acute treatment of burn wound infections and downstream bacterial complications…

4 months ago

NextStep Arthropedix to Launch TheRay™ Hip System

NextStep Arthropedix, a growing orthopedics company, announces the launch of TheRay™ Collared and Collarless Hip System. AKRON, Ohio, July 15, 2024…

4 months ago

Recce Pharmaceuticals Reports Positive Data from Phase I/II Urinary Tract Infection (UTI) / Urosepsis Rapid Infusion Trial of RECCE® 327

Results demonstrate efficacy on bacterial growth in participants injected with RECCE® 327 (R327) at the highest tested dose of 4,000mgNo…

5 months ago

Kane Biotech Makes First Commercial Sale of revyve™ Antimicrobial Wound Gel to ProgenaCare Global

Kane Also Signs Long-Term Manufacturing Agreement With Halo PharmaWINNIPEG, Manitoba, June 27, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-…

5 months ago

Lilly collaborates with OpenAI to discover novel medicines to treat drug-resistant bacteria

INDIANAPOLIS, June 25, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced a collaboration with OpenAI that will allow…

5 months ago

Recce Pharmaceuticals Receives Ethics Approval to Broaden RECCE® 327 Gel Trials Across all Topical Bacterial Skin Infections

Positions RECCE® 327 (R327) gel as a potential broad topical therapeutic for all bacterial skin infectionsHuman Research Ethics Committee approval…

5 months ago

Recce Pharmaceuticals Announces Addition of RECCE® 327 to The World Health Organization’s List of Antibacterial Products in Clinical Development

Inclusion underscores significance of RECCE® 327 (R327) in combating antimicrobial resistance and its potential to treat broad range of life-threatening…

5 months ago

AUROBAC THERAPEUTICS APPOINTS SCIENTIFIC ADVISORY BOARD

The newly formed Scientific Advisory Board chaired by Dr. Marco Taglietti will provide technical and strategic guidance to support AUROBAC’s…

5 months ago

Canopy expands real-time wearable safety from hospitals to home health

Leading health systems expand staff safety initiatives by deploying Canopy's real-time support network beyond hospital walls PALO ALTO, Calif., June…

5 months ago

Recce Pharmaceuticals Completes Dosing Additional Cohort in Phase I/II UTI/Urosepsis Rapid Infusion Trial

Six additional participants intravenously dosed with RECCE® 327 (R327) at 4,000mg over 20 minutes – highest dosage to date in…

5 months ago